What is the prevalence of Amyloidosis?

The prevalence of amyloidosis is difficult to pinpoint precisely due to the heterogeneity of its subtypes, but it is generally classified as a group of rare diseases with an estimated global prevalence ranging from 1 in 10,000 to 1 in 100,000 individuals depending on the specific type.

Understanding Prevalence and Incidence

Because amyloidosis encompasses several distinct conditions—such as AL (light chain) amyloidosis, ATTR (transthyretin) amyloidosis, and AA amyloidosis—there is no single global incidence rate. AL amyloidosis is the most common form in developed countries, with an estimated annual incidence of approximately 8 to 12 per million person-years. Conversely, hereditary ATTR amyloidosis shows significant geographic variation, with higher clusters observed in specific populations, such as in parts of Portugal, Japan, and Sweden due to founder effects.

Demographics and Onset

Amyloidosis is predominantly a disease of adulthood, with the median age of onset typically occurring between 50 and 70 years. While some hereditary forms can manifest earlier, pediatric cases are exceptionally rare. Gender distribution varies by subtype; for instance, AL amyloidosis shows a slight male predominance, while the progression and clinical presentation of the disease can differ significantly between men and women.

The Challenge of Data Accuracy

Accurate prevalence data for amyloidosis is hampered by frequent misdiagnosis or late diagnosis, as symptoms often mimic more common age-related conditions like heart failure or neuropathy. Consequently, many experts believe the true prevalence is higher than current clinical registries suggest. At DiseaseMaps.org, our community of 254 members provides a vital, real-world perspective that complements official clinical data, highlighting the diverse lived experiences of patients who often face long diagnostic journeys before reaching a specialist.

Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

• Orphanet: Portal for rare diseases and orphan drugs


• NIH Genetic and Rare Diseases Information Center (GARD)


• Amyloidosis Foundation